Larimar Therapeutics director buys 8,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Larimar Therapeutics, Inc. (LRMR) director Frank E. Thomas purchased 8,000 shares of common stock on November 11, 2026, at $2.7250 per share. His directly held position following the purchase was 15,000 shares. No Rule 10b5-1 plan is reported for the purchase.
Insider Trade Summary
Net Buyer: 8,000 shares
Net Buy
1 txn
Insider
THOMAS FRANK E
Role
Director
Bought
8,000 shs ($22K)
Increase in Position
114.3%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 8,000 | $2.725 | $22K |
Holdings After Transaction:
Common Stock — 15,000 shares (Direct)
Holdings Before and After:
Common Stock, 7,000 to 15,000 shares (Direct)
Other Insiders: 6 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Key Figures
Shares purchased: 8,000 shares
Purchase price: $2.7250 per share
Direct shares following transaction: 15,000 shares
3 metrics
Shares purchased
8,000 shares
Common stock purchased on November 11, 2026
Purchase price
$2.7250 per share
Common stock purchase on November 11, 2026
Direct shares following transaction
15,000 shares
Frank E. Thomas's directly held position following the purchase
Key Terms
Rule 10b5-1 plan
1 terms
Rule 10b5-1 plan regulatory
"No Rule 10b5-1 plan is reported for the purchase"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.